First Tissue-Agnostic Drug Approval Issued

被引：28
|
作者：
Poh, Alissa
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 07期
关键词：
D O I：
10.1158/2159-8290.CD-NB2017-078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The PD-1 inhibitor pembrolizumab received accelerated approval for adult and pediatric patients with solid tumors that are mismatch repair-deficient or microsatellite instability-high. This is the first time the FDA has greenlighted a drug based not on tumor type, but on a common biomarker. ©2017 American Association for Cancer Research.
引用
收藏
页码：656 / 656
页数：1
相关论文
共 50 条
12345